UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,736	10/11/2006	Michael V. Agrez	65350US(54086)	9415
	7590 08/15/201 NGELL PALMER & D	EXAMINER		
P.O. BOX 5587	' 4	DUFFY, BRADLEY		
BOSTON, MA 02205			ART UNIT	PAPER NUMBER
			1643	
			MAIL DATE	DELIVERY MODE
			08/15/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)
10/575,736	AGREZ, MICHAEL V.
Examiner	Art Unit
BRAD DUFFY	1643

	BRAD DUFFY	1643				
The MAILING DATE of this communication appea	rs on the cover sheet with the c	correspondence address				
THE REPLY FILED <u>01 August 2011</u> FAILS TO PLACE THIS API	PLICATION IN CONDITION FOR	ALLOWANCE.				
1. The reply was filed after a final rejection, but prior to or on the application, applicant must timely file one of the following reapplication in condition for allowance; (2) a Notice of Appear for Continued Examination (RCE) in compliance with 37 CF periods:	plies: (1) an amendment, affidavi I (with appeal fee) in compliance	t, or other evidence, which places the with 37 CFR 41.31; or (3) a Request				
a) \square The period for reply expires 3 months from the mailing date of	the final rejection.					
b) The period for reply expires on: (1) the mailing date of this Adno event, however, will the statutory period for reply expire lat Examiner Note: If box 1 is checked, check either box (a) or (b)	er than SIX MONTHS from the mailing	g date of the final rejection.				
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL						
2. The Notice of Appeal was filed on A brief in compli	ance with 37 CER 41 37 must be	filed within two months of the date of				
filing the Notice of Appeal (37 CFR 41.37(a)), or any extens a Notice of Appeal has been filed, any reply must be filed w AMENDMENTS	ion thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since				
3. X The proposed amendment(s) filed after a final rejection, but	t prior to the date of filing a brief,	will not be entered because				
(a) 🔀 They raise new issues that would require further cons		ΓE below);				
(b) $igotimes$ They raise the issue of new matter (see NOTE below	•					
(c) M They are not deemed to place the application in bette appeal; and/or	(c) 🔀 They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for					
(d) They present additional claims without canceling a co	rresponding number of finally reje	ected claims.				
NOTE: See Continuation Sheet. (See 37 CFR 1.11)	and 41.33(a)).					
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).						
5. Applicant's reply has overcome the following rejection(s):						
6. Newly proposed or amended claim(s) would be allo	wable if submitted in a separate,	timely filed amendment canceling the				
non-allowable claim(s). For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1,86-90, 92-96, 98-99, 101, 104-106 and 108.						
Claim(s) withdrawn from consideration:						
 AFFIDAVIT OR OTHER EVIDENCE The affidavit or other evidence filed after a final action, but I because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 						
The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).						
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.						
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s)						
13. Other:	10/56/08) Paper No(s)					
/Misook Yu/						
Supervisory Patent Examiner, Art Unit 1642						

Continuation of 3. NOTE: Applicant's proposed amendment, if entered, would require further consideration and/or search and may contain new matter e.g., with respect to the amendment to claim 1 to add: wherein the binding domain of the beta2 integrin subunit for the ERK2 MAP kinase is respectively provided by the amino acid sequence KEKLKSQWNNDNPLFK (SEQ ID No. 11), RARAKWDTANNPLYK (SEQ ID No. 5), RSRARYEMASNPLYR (SEQ ID NO. 6) or RSKAKWQTGNPLYR (SEQ ID No. 4). For example, in addition to further sequence searching, the amendment would require further search and consideration as it appears that the amendment to recite that the sequence of SEQ ID NO:4 is a binding domain of the beta2 integrin subunit introduces new matter as the specification sets forth at page 18, lines 17 and 18 that the amino acid sequence of SEQ ID NO:4 is the binding domain of beta6 integrin. Accordingly, the amendment is not deemed to place this application in better form for appeal by materially reducing or simplifying the issues for appeal.

Continuation of 11. does NOT place the application in condition for allowance because:

The request for reconsideration is predicated upon entry of the proposed amendment; therefore, as the amendment has not been entered, Applicant's request is presently moot.